Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Oxygenta Pharmaceutical's annualized net income for the quarter that ended in Jun. 2026 was ₹-84 Mil. Oxygenta Pharmaceutical's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹-427 Mil. Therefore, Oxygenta Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was N/A%.
The historical rank and industry rank for Oxygenta Pharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:
BOM:524636's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.89 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Oxygenta Pharmaceutical Return-on-Tangible-Equity Related Terms
Oxygenta Pharmaceutical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Oxygenta Pharmaceutical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524636 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Oxygenta Pharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxygenta Pharmaceutical Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Oxygenta Pharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Oxygenta Pharmaceutical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Oxygenta Pharmaceutical (BOM:524636) has a Return-on-Tangible-Equity of 0.00% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oxygenta Pharmaceutical and its competitors. According to the industry distribution chart, Oxygenta Pharmaceutical ranks #999999 out of 901 companies in the Drug Manufacturers industry.
Is Oxygenta Pharmaceutical's Return-on-Tangible-Equity too high?
Oxygenta Pharmaceutical's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Oxygenta Pharmaceutical ranks #999999 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Oxygenta Pharmaceutical has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oxygenta Pharmaceutical's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Oxygenta Pharmaceutical ranks #999999 out of 901 companies for Return-on-Tangible-Equity. This places Oxygenta Pharmaceutical in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oxygenta Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxygenta Pharmaceutical's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxygenta Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical (BOM:524636) is currently considered Possible Value Trap. The stock's GF Value™ is ₹83.92, compared to a current price of ₹49.04 — trading 41.6% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Oxygenta Pharmaceutical's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Oxygenta Pharmaceutical (BOM:524636), the current Return-on-Tangible-Equity is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxygenta Pharmaceutical (BOM:524636) Overvalued in 2026?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical stock appears to be undervalued.
The current stock price of ₹49.04 is trading 41.6% below its estimated GF Value™ of ₹83.92.
GuruFocus considers Oxygenta Pharmaceutical to be Possible Value Trap.
Key valuation signals for BOM:524636:
Return-on-Tangible-Equity: 0.00%
GF Value™: ₹83.92 vs. price of ₹49.04 (41.6% below fair value)
No single metric tells the full story. See the BOM:524636 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of is engaged in manufacturing and selling of Pharmaceutical, medical, and veterinary preparations. The Company has one reportable segment, which is Pharmaceutical. The group carries out its business operations within India.
38GF Score
Get the complete analysis for BOM:524636
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524636 has been successfully added to your 
